Health-related quality of life in hypertension: Impact of a pharmacy intervention programme

Journal of Clinical Pharmacy and Therapeutics

Volumn 30, Issue 4, 2005, Pages 355-362

  Côté, Isabelle ^a,b   Moisan, J ^a   Chabot, Isabelle ^a,c   Grégoire, Jean Pierre ^a  

^a LAVAL UNIVERSITY   (Canada)

^b i3 Global   (Canada)

^c MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Assessment; Hypertension; Intervention; Pharmacy; Quality of life

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ANXIETY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEALTH PROGRAM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PHARMACY; PHYSICAL ACTIVITY; PILOT STUDY; QUALITY OF LIFE; SHORT FORM 36; SOCIOECONOMICS; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; CANADA; CLINICAL TRIAL; HEALTH STATUS; INCOME; INTERVENTION STUDY; MIDDLE AGED; PATIENT EDUCATION;

AGED; ANXIETY; COHORT STUDIES; FEMALE; HEALTH STATUS; HUMANS; HYPERTENSION; INCOME; INTERVENTION STUDIES; MALE; MENTAL HEALTH; MIDDLE AGED; PATIENT EDUCATION; PHARMACEUTICAL SERVICES; QUALITY OF LIFE; QUEBEC;

EID: 26944451370     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2005.00663.x     Document Type: Article

References (25)

1. Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P. (1997) Awareness, treatment, and control of hypertension in Canada. American Journal of Hypertension, 10 (Pt 1), 1097-1102.
2. Burt VL, Whelton R, Roccella EL et al. (1995) Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension, 25, 305-313.
3. Bogden PE, Abbott RD, Williamson P, Onopa JK, Koontz LM (1998) Comparing standard care with a physician and pharmacist team approach for uncontrolled hypertension. Journal of General Internal Medicine, 13, 740-745.
4. Carter BL, Barnette DJ, Chrischilles E, Mazzotti GJ, Asali ZJ (1997) Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. Pharmacotherapy, 17, 1274-1285.
5. Erickson SR, Slaughter R, Halapy H (1997) Pharmacists' ability to influence outcomes of hypertension therapy. Pharmacotherapy, 17, 140-147.
6. Chabot I, Moisan J, Grégoire JP, Milot A (2003) Pharmacist intervention program for control of hypertension. Annals of Pharmacotherapy, 37, 1186-1193.
7. Guyatt GH, Feeny DH, Patrick DL (1993) Measuring health-related quality of life. Annals of Internal Medicine, 118, 622-629.
8. Green LW, Kreuter MW (1991) Health promotion planning: an educational and environmental approach, 2nd edn. Mountain View, CA: Mayfield Publishing Company.
9. Dauphinee S, Gauthier L, Gandek B, Magnan L, Pierre U (1997) Readying a US measure of health status, the SF-36, for use in Canada. Clinical and Investigative Medicine. Medecine Clinique et Experimentale, 20, 224-238.
10. Ware JJ (1996) The SF-36 Health Survey. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. Philadelphia, PA: Lippincott-Raven, 337-345.
11. Santé Q, Lavallée C, Bellerose C, Camirand J, Caris P, (sous la direction de) (1995) Aspects sociaux reliés àla santé, Rapport de l'Enquête sociale et de santé 1992-1993, Vol. 2. Montréal: Ministère de la Santé et des Services sociaux, Gouvernement du Québec.
12. Belsley D, Kuh E, Welsch R (1980) Regression diagnostics: identifying influential data and sources of collinearity. New York: Wiley.
13. Palmer A, Fletcher A, Hamilton G, Muriss S, Bulpitt C (1990) A comparison of verapamil and nifedipine on quality of life. British Journal of Clinical Pharmacology, 30, 365-370.
14. Palmer AJ, Fletcher AE, Rudge PJ, Andrews CD, Callaghan TS, Bulpitt CJ (1992) Quality of life in hypertensives treated with atenolol or captopril: a double-blind crossover trial. Journal of Hypertension, 10, 1409-1416.
15. Paran E, Anson O, Neumann L (1996) The effects of replacing beta-blockers with an angiotensin converting enzyme inhibitor on the quality of life of hypertensive patients. American Journal of Hypertension, 9 (Pt 1), 1206-1213.
16. Perry HM Jr, Hall WD, Benz JR et al. (1994) Efficacy and safety of atenolol, enalapril, and isradipine in elderly hypertensive women. American Journal of Medicine, 96, 77-86.
17. Testa MA, Anderson RB, Nackley JF, Hollenberg NK, Quality-of-Life Hypertension Study Group (1993) Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. New England Journal of Medicine, 328, 907-913.
18. Testa MA, Hollenberg NK, Anderson RB, Williams GH (1991) Assessment of quality of life by patient and spouse during antihypertensive therapy with atenolol and nifedipine gastrointestinal therapeutic system. American Journal of Hypertension, 4 (Pt 1), 363-373.
19. Mehos BM, Saseen JJ, MacLaughlin EJ (2000) Effect of pharmacist intervention and initiation of home blood pressure monitoring in patients with uncontrolled hypertension. Pharmacotherapy, 20,1384-1389.
20. Jaeschke R, Singer J, Guyatt GH (1989) Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials, 10, 407-415.
21. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D (1999) Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics, 15, 141-155.
22. Taylor DW, Sackett DL, Haynes RB, Johnson AL, Gibson ES, Roberts RS (1978) Compliance with antihypertensive drug therapy. Annals of the New York Academy of Sciences, 304, 390-403.
23. Cook TD, Campbell DT (1979) Quasi-experimentation: design and analysis issues for field settings. Boston, MA: Houghton Mifflin Company.
24. Ware J, Snow K, Kosinski M, Gandek B (1993) SF-36 health survey manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Center.
25. Côté I, Grégoire JP, Moisan J, Chabot I, Lacroix G (2003) Cost-benefit analysis of a pharmacy-based health promotion program in hypertension. Pharmacoeconomics, 21, 415-428.